Fishawack Health

As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.

Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.

Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.

Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.

The experienced executive will expand our cross-functional omnichannel, data and analytics, and technology offerings, developing effective solutions to meet our clients’ evolving needs.

Fishawack Health bolsters its commercialization service offering with its largest addition to date, welcoming US-based policy, market access, and transformation leader Avalere.

Fishawack Health announces its expanded global Value, Evidence, and Access (VEA) capability for biopharmaceutical and medical technology companies, with a suite of end-to-end services spanning product lifecycle, coupled with unsurpassed geographic reach.

Fishawack Health welcomes FIDE, an independent organization providing its clients with insight from clinical key opinion leaders in inflammatory dermatology

Welcoming Sheena Amin-Liebman as our new Diversity and Inclusion Director. Sheena will play a vital role in creating an inspiring environment that empowers staff to better guide its clients in their work to improve health outcomes for the patients they serve.

Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.

Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.

Fishawack Health bolsters its strong strategic offering by acquiring PRMA Consulting – a global market access and HEOR consulting leader with significant expertise in US, EU, and Asia-Pacific markets

The Fishawack Group has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency.

The Fishawack Group has launched their new website, introducing the company’s new two-division structure, Fishawack Medical Communications and Fishawack Creative. The new site showcases the Group's capabilities as well as providing news, careers, and contact information for the expanding group, complementing Fishawack’s active presence on LinkedIn and Twitter.

In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the implications for products and portfolios across the development life cycle.

Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts provide insights on the trends, challenges and opportunities for biopharmaceutical companies, including why an interdisciplinary approach is needed to improve outcomes in oncology.

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative pricing models, including ensuring the model chosen meets the payer’s needs.

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?

Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.

Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.

In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.

Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.

With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.

A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset.

Leading dermatologists discuss the innovations shaping 5 chronic skin diseases—psoriasis, atopic dermatitis, alopecia areata, vitiligo, and hidradenitis suppurativa—and share the challenges and opportunities for biopharmaceutical companies developing innovative treatments.

With hepatitis cases on the rise, Dr Anthony Martinez, member of the International Hepatitis Education Program (IHEP), shares his perspective on the World Health Organization’s new strategy for hepatitis elimination by 2030 and reveals his dynamic and novel colocalization method designed to meet patients where they are.

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in a digital world.

Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness.

In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for measuring omnichannel maturity.

Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators.

Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the roles of sales representatives and MSLs can evolve to drive greater personalization.

During the COVID-19 pandemic, a new digital-first launch model emerged as a gamechanger for driving better customer experiences. Here, Senior Consultant Srividya Sekar; Senior Associate Consultant, Erin Johnstone; and Associate Consultant, Oliver Longstaff, discuss the benefits of the new model and how life science companies can leverage the benefits of digital communication early on to drive a connected and agile launch.

Dave Stuteville, Executive Vice President, Learning & Development, reveals the principles behind successfully training Sales Representatives and Medical Science Liaisons for a rapid biopharmaceutical product launch.

Milo Elmir, Managing Consultant, examines the trends changing the behaviors of 3 healthcare stakeholders—patients, payers, and healthcare professionals—and explores how building human-centered solutions will help biopharmaceutical and medical technology companies drive better engagement.

Annemarie Armstrong, Executive Vice President, US Head of Client Services, shares the key considerations for launching a first commercial product, particularly on a rapid timeline.

The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the right approach to help companies with breakthrough innovations in their pipeline build consumer confidence.

In our new publication, we speak to key opinion leaders and industry experts to uncover novel strategies for commercializing immunodermatology therapies in a crowded market landscape.

Sotiria Papanicolaou, Chief Consulting Officer at PRMA Consulting, a member of Fishawack Health, explains how the combination of digital innovation and expert insight are removing roadblocks and speeding up the generation of health technology assessments (HTA) and payer submissions for pharma.

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’ approaches to combatting the disease and explore the importance of a de-centralized strategy that overcomes the stigma preventing patients from seeking treatment.

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors.

In 2020, healthcare technology investment went into overdrive. We speak to Sunny Kumar, Partner at GSR Ventures, to find out how COVID‑19 has transformed the industry and whether healthcare technology can bring us one step closer to a value-based model of care.

Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can be an essential tool for medical affairs, bringing data to life and engaging patients and healthcare professionals in novel and more meaningful ways.

Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience.

The consumer industry has long been leveraging the power of social media influencers with enormous success. But can the highly regulated healthcare industry achieve the same results? Daniel Brackins explores the influencer marketing opportunities for life science companies and answers your questions.

In this e-book, we answer the difficult questions around vaccine hesitancy. Our consultants and commercial experts explore the behavioural science and reveal strategies for improving uptake.

Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention.

In this edition of Delta magazine, we explore how rapid digitalization has transformed the care pathway and reveal how life science companies can succeed in the digital age.

Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.

Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization.